“Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial”, J of Skin, vol. 9, no. 2, p. s525, Mar. 2025, doi: 10.25251/skin.10.supp.525.